Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inozyme Pharma, Inc. - Common Stock (NQ:INZY)

3.950 UNCHANGED
Streaming Delayed Price Updated: 1:09 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,139,889
Open 3.940
Bid (Size) 3.940 (4,353)
Ask (Size) 3.950 (532)
Prev. Close 3.950
Today's Range 3.940 - 3.950
52wk Range 0.7210 - 6.240
Shares Outstanding 61,729,666
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
From Brodsky & Smith LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire

Performance

YTD
+38.6%
+38.6%
1 Month
+303.3%
+303.3%
3 Month
+199.2%
+199.2%
6 Month
+37.2%
+37.2%
1 Year
-16.5%
-16.5%

More News

Read More
Gold Down Over 1%; Flowers Foods Posts Weak Earnings
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens
Via Stocktwits
Synergy CHC Corp. (NASDAQ: SNYR) Reports Strong Q1, Signals 2025 Expansion in GLP-1 and Global Markets – More Stocks Inside
Via AB Newswire
US Stocks Edge Higher; Consumer Sentiment Falls In May
Via Benzinga
INZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover
Via Investor's Business Daily
Exposures Product Safety
Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders
From Ademi & Fruchter LLP
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present at Upcoming Investor Conferences
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
From Inozyme Pharma Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Inozyme Pharma, Inc. - Common Stock publicly traded?
Yes, Inozyme Pharma, Inc. - Common Stock is publicly traded.
What exchange does Inozyme Pharma, Inc. - Common Stock trade on?
Inozyme Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Inozyme Pharma, Inc. - Common Stock?
The ticker symbol for Inozyme Pharma, Inc. - Common Stock is INZY on the Nasdaq Stock Market
What is the current price of Inozyme Pharma, Inc. - Common Stock?
The current price of Inozyme Pharma, Inc. - Common Stock is 3.950
When was Inozyme Pharma, Inc. - Common Stock last traded?
The last trade of Inozyme Pharma, Inc. - Common Stock was at 05/19/25 01:09 PM ET
What is the market capitalization of Inozyme Pharma, Inc. - Common Stock?
The market capitalization of Inozyme Pharma, Inc. - Common Stock is 243.83M
How many shares of Inozyme Pharma, Inc. - Common Stock are outstanding?
Inozyme Pharma, Inc. - Common Stock has 244M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.